Previous 10 | Next 10 |
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., Pr...
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., Pr...
Yumanity Therapeutics (NASDAQ:YMTX): Q3 GAAP EPS of -$0.97 beats by $0.25. Revenue of $1.64M (-50.5% Y/Y) misses by $0.29M. Press Release For further details see: Yumanity Therapeutics EPS beats by $0.25, misses on revenue
Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company anticipates initiating Phase 2 clinical trial of YTX-7739 in patients with Park...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied Friday, led by technology and communication services, but the major averages finished lower for the week on escalating inflati...
Yumanity Therapeutics (NASDAQ:YMTX) announced the grant of non-statutory stock options to two employees for the purchase of up to total of 2K shares of common stock. The options will vest over four years, with 25% of shares vesting on the first anniversary of the employee's new hire...
AerSale (NASDAQ:ASLE) -36% on Q3 earnings release. Purple Innovation (NASDAQ:PRPL) -32% on Q3 earnings release. Poshmark (NASDAQ:POSH) -30% on Q3 earnings release. Upstart Holdings (NASDAQ:UPST) -23% on Q3 earnings release. AnPac Bio-Medical S...
Yumanity Therapeutics (NASDAQ:YMTX) posts topline results from Phase 1b trial for YTX-7739 in patients with Parkinson’s Disease (PD). Shares fall more than 5% premarket. The Phase 1b trial was a randomized, placebo-controlled, double-blind multi dose study to investigate...
YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles and a safety profile with no se...
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to an employee of non-stat...